Charcot Neuroarthropathy

1. Clinical Overview

Summary

Charcot Neuroarthropathy (CN), also known as Charcot foot or neuropathic arthropathy, is a progressive, non-infectious, destructive arthropathy affecting the bones, joints, and soft tissues of the foot and ankle in patients with peripheral neuropathy. [1,2] The condition is most commonly associated with long-standing diabetes mellitus but can occur in any condition causing peripheral sensory neuropathy. CN represents one of the most devastating complications of diabetic foot disease, with potentially catastrophic consequences including severe deformity, ulceration, infection, and ultimately lower limb amputation. [3,4]

The hallmark of acute Charcot is a red, hot, swollen foot in a patient with peripheral neuropathy, often triggered by minor trauma that goes unnoticed due to sensory loss. [5] This acute inflammatory phase is characterized by unregulated osteoclastic activity leading to aggressive bone resorption, fractures, and joint dislocation. [6] If the patient continues to bear weight on the affected foot during this critical phase, progressive architectural collapse occurs, resulting in characteristic deformities such as the "rocker bottom" foot—a convex plantar surface caused by midfoot collapse. [7,8]

Early recognition and immediate offloading are paramount to prevent irreversible deformity. [9] The gold standard treatment during the acute phase is prolonged immobilization in a total contact cast (TCC), which arrests bone destruction and allows consolidation in an anatomically acceptable position. [10] Delayed diagnosis or inadequate treatment leads to chronic deformity with plantar prominence, predisposing to ulceration over pressure points, secondary osteomyelitis, and amputation risk approaching 30-40% in severe cases. [11,12]

The economic and personal burden is substantial, with CN patients requiring extensive multidisciplinary care, prolonged periods of immobilization (typically 4-9 months), custom orthotic devices for life, and in many cases, complex reconstructive surgery. [13,14] Despite advances in understanding and management, CN remains underdiagnosed and undertreated, with studies showing average diagnostic delays of 29 weeks from symptom onset. [15]

Key Facts

Epidemiology

• Prevalence: 0.08% to 13% of diabetic patients, depending on screening methodology and population studied. [16]
• Most commonly affects patients with diabetes duration > 10 years and established peripheral neuropathy. [17]
• Peak incidence: 50-60 years of age.
• Gender distribution: Slight male predominance (1.3:1).
• Bilateral involvement: 20-40% of cases, often sequential rather than simultaneous. [18]

Pathophysiology Essentials

• Mandatory prerequisite: Dense peripheral sensory neuropathy (vibration perception threshold > 25V). [19]
• Paradoxical requirement: Good vascular supply with palpable pulses (inflammation requires blood flow). [6]
• Trigger: Minor trauma (sprain, surgery, ulcer healing) in insensate foot initiates inflammatory cascade. [5]
• Molecular mechanism: Upregulation of RANK-L (Receptor Activator of Nuclear Factor Kappa-B Ligand) drives excessive osteoclast activity. [20]
• Result: Unregulated bone resorption > bone formation → soft, fragile bone ("like custard") that fractures and collapses under physiological loads.

Diagnostic Hallmarks

• Temperature differential: > 2°C increase compared to contralateral foot (measured with infrared thermometer). [21]
• Clinical triad: Warmth + Swelling + Erythema in a neuropathic foot.
• Absence of infection markers: Normal or minimally elevated inflammatory markers; patient systemically well.
• Radiographic evolution: Initial X-rays may be normal; MRI shows bone marrow edema preceding radiographic changes. [22]

Anatomical Patterns (Sanders & Frykberg Classification)

• Zone I (Forefoot): 15% - Metatarsophalangeal/interphalangeal joints - best prognosis.
• Zone II (Midfoot): 40% - Tarsometatarsal (Lisfranc) joint - most common, highest risk of rocker bottom deformity.
• Zone III (Hindfoot): 30% - Subtalar/talonavicular joints - severe instability, difficult to brace.
• Zone IV (Ankle): 10% - Tibiotalar joint - worst prognosis, often requires amputation.
• Zone V (Calcaneus): 5% - Calcaneal avulsion fractures.

Management Principles

• Acute phase: Immediate non-weight bearing and total contact casting until "fire goes out" (temperature normalizes). [9,10]
• Duration: Typically 4-9 months of immobilization.
• Endpoint: Temperature within 1°C of contralateral foot + radiographic consolidation.
• Chronic phase: Lifelong custom orthotic footwear (Charcot Restraint Orthotic Walker - CROW).
• Surgical reconstruction: Reserved for chronic deformity causing recurrent ulceration or unbraceability.

Clinical Pearls

"Assume Charcot Until Proven Otherwise": Any diabetic patient with a red, hot, swollen foot should be presumed to have acute Charcot until proven otherwise, regardless of alternative suspected diagnoses. This "guilty until proven innocent" approach prevents the catastrophic consequences of delayed treatment. [23]

"The Painless Disaster": The absence of significant pain despite massive bone destruction is pathognomonic for Charcot. Patients often present casually stating "I noticed my foot changed shape" while walking on multiple fractures and dislocations. This disconnect between structural damage and symptoms reflects the severity of underlying neuropathy.

"It's Not Infection—Unless It Is": If there is NO ulcer, NO portal of entry, and the patient is SYSTEMICALLY WELL with normal/minimally elevated inflammatory markers, it is Charcot not cellulitis. However, 30-40% of Charcot patients develop ulcers (particularly those with rocker bottom deformity), creating "acute-on-Charcot" where infection supervenes on underlying neuroarthropathy. [11]

"The Elevation Test": Elevate the affected leg for 5 minutes. Charcot erythema fades significantly (dependent rubor due to AV shunting); cellulitis erythema persists. This simple bedside test can differentiate inflammatory hyperemia from true infection. [24]

"Bilateral Disease = Double Trouble": Once one foot develops Charcot, the contralateral foot has a 20-40% risk over the patient's lifetime. [18] Temperature monitoring of the "good foot" is essential—a temperature rise > 2°C should trigger immediate offloading even before symptoms develop.

"The Race Against Gravity": From the moment diagnosis is made, it's a race to immobilize the foot before the midfoot arch collapses. Once the arch inverts (rocker bottom), the cuboid and navicular become plantar prominences—skin not designed to bear weight. Ulceration is almost inevitable, and with it comes osteomyelitis and amputation risk. We don't treat Charcot to save the bones; we treat it to prevent the ulcer. [7]

"Operating on Cheese": Never perform elective surgery on an acutely inflamed Charcot foot (Eichenholtz Stage I). The bone quality is so poor that implants will fail. As one senior foot surgeon notes: "Operating on acute Charcot is like trying to screw into soft cheese—the hardware will just pull out." Wait for quiescence (Stage II-III). [25]

"The Cast is the Treatment, Not the Bridge": Total contact casting is not a temporizing measure—it IS the definitive treatment for acute Charcot. The cast must be worn continuously for months (average 5.5 months) until temperature and inflammatory markers normalize. Patients who terminate casting early due to frustration are virtually guaranteed to develop deformity. [10]

"Good Circulation, Bad Outcome": Paradoxically, Charcot requires good arterial perfusion—the inflammatory response needs blood flow. Patients with critical ischemia don't get Charcot; they get gangrene. Charcot patients typically have bounding pulses and warm feet. This has treatment implications: offloading and immobilization work because tissue perfusion allows healing. [6]

---

2. Epidemiology

Incidence and Prevalence

The true prevalence of Charcot neuroarthropathy remains uncertain due to significant underdiagnosis and variation in screening practices across healthcare systems. [16] Reported prevalence rates range widely from 0.08% to 13% of diabetic patients, with the variation reflecting differences in study methodology, diagnostic criteria, and population characteristics. [1,16]

Population-Specific Data:

• General diabetic population: 0.1-0.9% develop Charcot arthropathy. [1]
• High-risk diabetic cohorts (> 10 years diabetes, established neuropathy): 13-29%. [17]
• Diabetic foot clinic populations: 3-8% have evidence of Charcot (many asymptomatic/chronic). [2]
• Incidence rate: Approximately 1.5-3 cases per 1,000 diabetic patient-years in developed countries. [16]

The actual burden is likely higher than documented, as many patients with Charcot are misdiagnosed initially (commonly as cellulitis or gout), and some patients with mild disease in zones of lower mechanical stress (Zone I - forefoot) may never present or be diagnosed. [15]

Risk Factors

Mandatory Prerequisites

1. Peripheral Sensory Neuropathy: Present in > 99% of cases. [19]

   • Vibration perception threshold (VPT) > 25 volts strongly associated
   • Loss of protective sensation (10g monofilament)
   • Impaired proprioception and pain perception

2. Adequate Vascular Perfusion: Intact arterial supply is required. [6]

   • Palpable pedal pulses in 80-85% of Charcot patients
   • Ankle-brachial index (ABI) > 0.6 typically
   • Peripheral arterial disease actually protective against Charcot (insufficient perfusion for inflammatory response)

Major Risk Factors

• Diabetes duration: > 10 years in 75% of cases [17]
• Previous ulceration: 2.5-fold increased risk [11]
• History of Charcot in contralateral foot: 20-40% develop bilateral disease [18]
• Renal disease: End-stage renal disease increases risk 3-fold [26]
• Recent trauma/surgery: Triggers acute Charcot in susceptible patients [5]
• Kidney/pancreas transplantation: Immunosuppression and osteopenia increase risk

Demographic Factors

• Age: Peak incidence 50-60 years; mean age at diagnosis 57 years
• Sex: Male:Female ratio approximately 1.3:1 [18]
• Ethnicity: Higher rates reported in Hispanic and Native American populations in US studies
• Body mass index: Obesity (BMI > 30) increases mechanical stress on compromised bone

Natural History

Bilateral Involvement Bilateral Charcot occurs in 20-40% of patients, though rarely simultaneously. [18] The contralateral foot typically develops Charcot within 1-5 years of the initial episode. This emphasizes the need for:

• Regular temperature monitoring of the unaffected foot
• Patient education on early warning signs
• Prophylactic orthotic protection in some high-risk cases

Long-term Outcomes Without early intervention:

• Deformity development: 70-90% progress to structural deformity [7]
• Ulceration: 40-60% develop plantar ulcers over bony prominences [11]
• Amputation: 15-30% require major amputation within 5 years [12]
• Mortality: 5-year mortality 28-29%, comparable to many malignancies [4]

With early diagnosis and appropriate offloading:

• Deformity prevention: 60-75% achieve anatomically acceptable consolidation [9,10]
• Ulcer-free survival: 70-80% at 5 years with appropriate footwear [13]
• Amputation reduction: Major amputation reduced to 5-10% [9]

Economic Burden

Charcot neuroarthropathy imposes substantial economic costs:

• Acute phase treatment: $15,000-$25,000 (serial casting, imaging, multidisciplinary care)
• Reconstructive surgery: $30,000-$60,000 per procedure
• Lifetime orthotic costs: $2,000-$5,000 annually
• Total lifetime cost: Estimated $100,000-$150,000 per patient [14]
• Lost productivity: Average 6-12 months inability to work during acute/reconstruction phases

The cost of missed diagnosis is even higher—patients progressing to ulceration and osteomyelitis incur treatment costs exceeding $200,000, with major amputation costs reaching $500,000 over the patient's remaining lifetime. [12]

---

3. Pathophysiology

Historical Theories

Understanding of Charcot neuroarthropathy has evolved significantly since Jean-Martin Charcot's original description in 1868 of neuropathic arthropathy in tabes dorsalis patients. Two classical theories competed for decades:

1. Neurotraumatic Theory (German School)

• Loss of protective sensation allows repetitive microtrauma to accumulate unnoticed
• Absence of pain removes the body's warning system
• Impaired proprioception leads to abnormal joint loading and mechanical stress
• Continued ambulation on injured joints perpetuates destructive cycle
• Problem: Does not explain the acute inflammatory response or why fractures occur with minimal trauma

2. Neurovascular Theory (French School)

• Autonomic neuropathy causes loss of sympathetic vasomotor tone
• Arteriovenous shunting increases bone blood flow (hyperemia)
• Increased perfusion "washes out" bone minerals, causing osteopenia
• Weakened bone fractures under normal loads
• Problem: Does not explain why patients with intact circulation but no neuropathy don't develop Charcot

Modern Consensus: Both mechanisms contribute, but neither fully explains the aggressive, inflammatory nature of acute Charcot. Current understanding centers on immune-mediated osteoclastic bone resorption. [6,20]

The RANK-L/OPG Pathway (Unified Modern Theory)

The contemporary pathophysiological model explains Charcot as an unregulated inflammatory response to minor trauma in a susceptible (neuropathic, well-perfused) host. [20]

Step 1: The Trigger

• Minor trauma (sprain, twist, foot surgery, ulcer healing) in a neuropathic foot
• Patient unaware of injury due to sensory loss
• Continues weight-bearing on injured structures

Step 2: Inflammatory Cascade

• Local trauma releases pro-inflammatory cytokines:
  • TNF-α (Tumor Necrosis Factor-alpha)
  • IL-1β (Interleukin-1 beta)
  • IL-6 (Interleukin-6)
• These cytokines upregulate RANK-L expression

Step 3: RANK-L Activation

• RANK-L (Receptor Activator of Nuclear Factor Kappa-B Ligand) binds to RANK receptors on osteoclast precursors
• Stimulates osteoclast differentiation, activation, and survival
• Simultaneously, there is decreased production of OPG (Osteoprotegerin), the natural inhibitor of RANK-L
• Result: RANK-L/OPG ratio dramatically increases (up to 10-fold in acute Charcot) [20]

Step 4: Osteoclastic Bone Resorption

• Excessive osteoclast activity causes aggressive bone resorption
• Bone becomes osteopenic, structurally weak ("soft as custard")
• Fractures occur with minimal stress (even physiological weight-bearing)
• Fragments and debris accumulate ("bag of bones" appearance on X-ray)

Step 5: Architectural Collapse

• If weight-bearing continues, soft bones cannot maintain structure
• Midfoot arch collapses (most common)
• Ligamentous structures fail
• Joint dislocations occur
• Rocker bottom deformity results from plantar displacement of midfoot bones

Step 6: Resolution (if offloaded)

• With immobilization, inflammatory cytokines downregulate
• RANK-L/OPG ratio normalizes
• Osteoblastic activity increases
• Bone fragments consolidate (often in deformed position if presentation was delayed)
• Eichenholtz Stage II-III transition: Coalescence and reconstruction

The Role of Neuropathy

Peripheral neuropathy in Charcot is multifaceted:

Sensory Neuropathy

• Loss of protective pain sensation → injury goes unnoticed
• Impaired vibration/pressure perception → abnormal gait mechanics
• Allows continued weight-bearing during inflammatory phase (critical factor)

Motor Neuropathy

• Intrinsic foot muscle atrophy
• Biomechanical imbalance favoring long flexors/extensors
• Altered foot pressure distribution
• Development of clawing deformities and increased forefoot loading

Autonomic Neuropathy

• Loss of sympathetic tone → vasodilation and AV shunting
• Increased bone blood flow (perfusion needed for inflammation)
• Decreased sweating → dry, fissured skin (entry point for infection)
• Contributes to hyperemia seen clinically (warm, red foot)

Biomechanical Factors

Bone Quality in Diabetic Neuropathy Even before Charcot develops, diabetic neuropathic bone shows:

• Reduced bone mineral density: 10-15% lower than age-matched controls
• Impaired bone quality: Advanced glycation end-products (AGEs) accumulate in collagen
• Altered bone architecture: Trabecular thinning and cortical porosity
• Increased fracture susceptibility: Minor trauma causes disproportionate damage

Stress Concentration

• Midfoot (Lisfranc joint) bears tremendous load during push-off phase of gait
• Loss of intrinsic muscle support increases plantar pressure by 30-40%
• Repetitive stress in osteopenic bone → microfractures → acute inflammatory response

Genetic and Metabolic Factors

Genetic Susceptibility

• Not all diabetic patients with neuropathy develop Charcot (only 0.1-13%)
• Genetic polymorphisms in RANK-L, OPG, and inflammatory cytokine genes may increase susceptibility
• Human leukocyte antigen (HLA) associations reported in some populations
• Family clustering suggests hereditary component (incompletely understood)

Metabolic Contributors

• Hyperglycemia: Impairs bone formation and increases RANK-L expression
• Vitamin D deficiency: Common in diabetes; contributes to osteopenia
• Renal osteodystrophy: In diabetic nephropathy, further compromises bone quality
• Immunosuppression: Post-transplant patients at higher risk

---

4. Classification Systems

Eichenholtz Classification (Temporal Staging)

The Eichenholtz classification, described in 1966, remains the cornerstone for staging Charcot based on clinical and radiographic evolution. [27] It divides the natural history into three distinct stages:

Stage 0 (Prodromal) is critically important as it represents the window for intervention before structural damage occurs. However, it is also the most commonly missed stage because standard X-rays appear normal. [22] MRI showing bone marrow edema in a clinically inflamed neuropathic foot is diagnostic. Immediate offloading at Stage 0 can prevent fracture and deformity entirely.

Clinical Application:

• Temperature monitoring guides stage transition: > 2°C difference = active (Stage I); within 1°C = quiescent (Stage III)
• X-ray evolution lags behind clinical signs by 2-4 weeks
• Transition from Stage I to Stage II typically takes 3-4 months of offloading
• Premature termination of offloading can cause reactivation (return to Stage I)

Sanders & Frykberg Anatomical Classification

This system classifies Charcot by anatomical location, which correlates with prognosis and treatment complexity. [28]

Zone I: Forefoot (15% of cases)

• Joints involved: Metatarsophalangeal (MTP) and interphalangeal (IP) joints
• Deformity pattern: Splay foot, hammer/claw toes
• Prognosis: Best - often manageable with extra-depth shoes and toe box modifications
• Ulcer risk: Moderate - over toe tips or metatarsal heads
• Surgical need: Low

Zone II: Midfoot (40% of cases) - MOST COMMON

• Joints involved: Tarsometatarsal (Lisfranc) joint complex
• Deformity pattern: Rocker bottom foot (plantar arch collapse), medial/lateral column collapse
• Prognosis: Guarded - high risk of plantar prominence and ulceration
• Ulcer risk: HIGH - cuboid/navicular become plantar pressure points
• Surgical need: Moderate-High (if severe rocker bottom or recurrent ulceration)
• Clinical note: This is the pattern surgeons fear most—mechanical stress is maximal, and custom bracing is difficult

Zone III: Hindfoot (30% of cases)

• Joints involved: Subtalar, talonavicular, calcaneocuboid (Chopart joint)
• Deformity pattern: Varus/valgus instability, heel shift
• Prognosis: Poor - severe instability, difficult to brace
• Ulcer risk: High - lateral/medial malleolus prominence, heel
• Surgical need: High - often requires arthrodesis with superconstructs

Zone IV: Ankle (10% of cases)

• Joints involved: Tibiotalar (ankle) joint
• Deformity pattern: Ankle collapse, severe instability
• Prognosis: Worst - catastrophic mechanical failure
• Ulcer risk: Very high - malleolar ulceration common
• Surgical need: Very high - often requires tibiotalocalcaneal (TTC) arthrodesis or amputation
• Clinical note: Ankle Charcot has highest amputation rate (up to 50%)

Zone V: Calcaneus (5% of cases)

• Pattern: Calcaneal avulsion fractures, typically Achilles insertion
• Deformity: Loss of heel contour, calcaneal shortening
• Prognosis: Variable
• Management: Often conservative, may require Achilles lengthening

Combined Patterns: 10-15% of patients have involvement of multiple zones, which dramatically worsens prognosis and increases surgical complexity.

Brodsky Classification (Simplified Anatomical)

An alternative, simpler anatomical classification:

• Type 1: Forefoot and midfoot (85% of cases)
• Type 2: Hindfoot/ankle (15% of cases)
• Type 3A: Ankle with fragmentation
• Type 3B: Calcaneal fractures

Clinical Staging for Treatment (Modified from Rogers)

Acute Charcot (Eichenholtz 0-I)

• Temperature differential > 2°C
• Requires immediate offloading
• Surgery contraindicated

Subacute Charcot (Eichenholtz II)

• Temperature differential 1-2°C
• Transition phase
• Continue immobilization

Chronic Quiescent Charcot (Eichenholtz III)

• Temperature normalized (less than 1°C difference)
• Structurally stable
• Ready for definitive bracing or surgery if indicated

---

5. Clinical Presentation

Acute Charcot (Eichenholtz Stage 0-I)

Cardinal Presentation The classic presentation is a diabetic patient presenting with a unilaterally red, hot, swollen foot, often with minimal or no pain, and no clear recollection of injury. [5] This constellation in a patient with established neuropathy should trigger immediate suspicion for acute Charcot.

Clinical Hallmarks

1. Warmth (Most Reliable Sign)

• Temperature differential > 2°C compared to contralateral foot (sensitivity 90%, specificity 85%) [21]
• Use infrared thermometer for objective measurement (alternatively, back of examiner's hand)
• Temperature increase reflects hyperemia and inflammatory response
• Warmth persists until inflammation resolves (weeks to months)

2. Erythema

• Deep red to purple discoloration
• Dependent rubor: Fades significantly with leg elevation (vs. cellulitis which persists)
• Distribution: Diffuse across affected zone (not confined to dermatomal/vascular distribution)

3. Edema

• Diffuse swelling of foot and ankle
• Non-pitting initially (inflammatory), becomes pitting as inflammation progresses
• May extend to lower leg

4. Instability

• On palpation, affected joints feel "loose" or "unstable"
• Crepitus may be elicited (bone-on-bone grinding from fractures)
• In midfoot Charcot, the examiner can often feel abnormal motion at the Lisfranc joint
• Foot may have rubbery, malleable quality ("putty foot")

5. Pain (Variable)

• Paradoxically, often MINIMAL despite severe structural damage
• 30-40% report no pain whatsoever [5]
• When present, usually described as deep ache or pressure
• Lack of pain reflects profound sensory neuropathy
• Red flag: Severe pain in Charcot patient suggests superimposed infection

6. Absence of Infection Signs

• No portal of entry: No ulcer, cut, or puncture wound (if present, consider infection)
• Systemically well: No fever, rigors, or constitutional symptoms
• Inflammatory markers: CRP/ESR normal or mildly elevated (less than 50 mg/L typically)
• White cell count: Normal (vs. elevated in infection)

The Misdiagnosis Trap

Charcot Mimicking Cellulitis This is the most common and most catastrophic misdiagnosis. [15,23] Up to 30% of Charcot patients are initially treated for cellulitis, leading to diagnostic delays averaging 29 weeks.

How to Differentiate:

Bedside Test: Elevate the leg to 45° for 5 minutes. Charcot erythema fades significantly (dependent rubor from AV shunting); cellulitis erythema remains unchanged. [24]

Other Common Misdiagnoses:

• Acute gout: Differentiated by serum urate, joint aspiration (no crystals in Charcot)
• Septic arthritis: Joint aspiration sterile in Charcot
• DVT: Unilateral swelling, but Charcot has warmth and absent Homan's sign; D-dimer may be elevated in both
• Stress fracture: Similar mechanism but lacks diffuse inflammation and warmth

Chronic Charcot (Eichenholtz Stage III)

Structural Deformities

Rocker Bottom Foot (Midfoot Collapse)

• Reversal of longitudinal arch
• Convex plantar surface
• Cuboid and/or navicular become plantar prominences
• Talonavicular dislocation with plantar displacement
• Consequence: Skin under these bones not designed for weight-bearing → ulceration inevitable without protective footwear

Medial Column Collapse

• Medial longitudinal arch flattens
• Talar head prominence medially
• Forefoot abduction
• Severe cases: Foot appears "rocker-shaped" from side

Splay Foot

• Widening of forefoot
• Metatarsal splaying
• Difficulty fitting into standard shoes
• Increased transverse diameter by 1-2 cm

Varus/Valgus Deformity (Hindfoot Charcot)

• Ankle/hindfoot tilts medially (varus) or laterally (valgus)
• Severe instability
• Ulceration over malleoli
• Impossible to brace effectively without surgery

Equinus Deformity

• Ankle fixed in plantar flexion
• Achilles tendon contracture (from prolonged immobilization or primary pathology)
• Increased forefoot pressure
• Requires lengthening if causing ulceration

Clinical Features of Chronic Charcot

• Foot cool, non-erythematous (inflammation resolved)
• Fixed deformity (not reducible)
• Bony prominences palpable
• Callus formation over pressure points
• Ulceration risk dependent on deformity severity and footwear

Special Presentations

Acute-on-Chronic Charcot

• Previously quiescent Charcot reactivates
• Triggers: New trauma, ulcer, surgical intervention, excessive activity
• Foot becomes warm and swollen again
• Requires repeat offloading and immobilization

Open Charcot

• Ulceration overlying active Charcot
• Dual pathology: Neuropathic ulcer + unstable bone
• Extremely high risk: Osteomyelitis develops in 60-70% [11]
• Major amputation risk 40-50%
• Requires combined wound management and Charcot offloading

Bilateral Simultaneous Charcot

• Rare (5-10% of bilateral cases present simultaneously)
• Devastating for mobility (cannot offload onto "good" foot)
• Often requires wheelchair mobilization
• High risk of complications from immobility (DVT, deconditioning)

Post-surgical Charcot

• Develops after foot/ankle surgery in neuropathic patients
• Can occur even after minor procedures (bunionectomy, nail removal)
• Prevention: Prolonged postoperative offloading (minimum 8-12 weeks) in high-risk patients

---

6. Investigations

Clinical Assessment

Initial Clinical Examination

Vascular Assessment

• Palpate dorsalis pedis and posterior tibial pulses (should be present in Charcot)
• Absent pulses suggest PAD (makes Charcot less likely, ischemia more likely)
• Ankle-Brachial Index (ABI): Typically > 0.6 in Charcot patients
• Note: ABI can be falsely elevated in diabetics due to medial arterial calcification

Neuropathy Assessment

• 10g monofilament: Inability to sense indicates loss of protective sensation
• Vibration perception threshold (VPT): > 25V strongly associated with Charcot [19]
• Ankle reflexes: Typically absent
• Proprioception: Impaired (Romberg positive)

Temperature Measurement

• Infrared thermometer: Measure 4-5 sites on each foot (great toe, 1st MTH, 3rd MTH, midfoot, heel)
• Diagnostic threshold: > 2°C temperature differential between corresponding sites [21]
• Monitoring: Serial measurements guide treatment—normalizing temperature indicates resolution

Biomechanical Assessment

• Gait analysis: Abnormal loading patterns
• Foot pressure mapping: Identifies high-pressure zones (risk for future ulceration)
• Joint stability testing: Laxity, crepitus, instability

Laboratory Investigations

Blood Tests

Inflammatory Markers

• CRP: Normal or mildly elevated (less than 50 mg/L) in pure Charcot [23]
  • If CRP > 100 mg/L, strongly consider superimposed infection
• ESR: May be mildly elevated (typically less than 40 mm/hr)
• White cell count: Should be normal in Charcot alone

Metabolic Panel

• HbA1c: Assess glycemic control (often suboptimal in Charcot patients)
• Renal function: Diabetic nephropathy common; affects prognosis
• Vitamin D: Deficiency contributes to bone fragility

Bone Markers (Research/Specialized Centers)

• RANK-L/OPG ratio: Elevated in acute Charcot [20]
• C-terminal telopeptide (CTX): Marker of bone resorption (elevated)
• Procollagen type 1 N-terminal propeptide (P1NP): Marker of bone formation
• Not routinely available or necessary for diagnosis

When Infection Suspected

• Blood cultures: If systemically unwell
• Wound culture: If ulcer present (swab often contaminated; deep tissue/bone biopsy preferred)
• Procalcitonin: More specific than CRP for bacterial infection

Imaging

Plain Radiography

Technique

• Weight-bearing AP and lateral views: Essential to assess deformity and alignment
• If patient cannot weight-bear, obtain standing views with walker support
• Comparison views of contralateral foot helpful

Stage 0 (Prodromal)

• Findings: Normal X-ray
• Limitation: Does not exclude Charcot—bone marrow edema precedes radiographic changes by 2-4 weeks [22]
• Action: If clinical suspicion high and X-ray normal, proceed to MRI

Stage I (Development/Fragmentation)

• Fractures: Metatarsals, tarsals, often multiple
• Joint subluxation/dislocation: Lisfranc joint most common
• Fragmentation: Bone debris, comminuted fracture patterns
• Bone resorption: Osteolysis, "disappearing bone"
• Soft tissue swelling

Stage II (Coalescence)

• Callus formation: Periosteal and endosteal new bone
• Fragment fusion: Fracture healing begins
• Sclerosis: Increased bone density
• Reduced soft tissue swelling

Stage III (Consolidation)

• Remodeling complete: Smoothed bone edges
• Ankylosis: Joint fusion common (fibrous or bony)
• Deformity fixed: Rocker bottom, collapse patterns visible
• Osteophytes: Extensive spurring

Radiographic Patterns by Zone

• Zone II (Lisfranc): "Stacked coins" sign—tarsal bones overlap; loss of midfoot arch height
• Zone III (Chopart): Talonavicular dislocation, hindfoot collapse
• Zone IV (Ankle): Tibiotalar subluxation, fragmentation

Magnetic Resonance Imaging (MRI)

Indications

• Suspected Stage 0 Charcot with normal X-ray (gold standard) [22]
• Differentiating Charcot from osteomyelitis (notoriously difficult clinically)
• Preoperative planning: Assess extent of bone involvement

Charcot MRI Findings

• Bone marrow edema: Low T1, high T2/STIR signal in multiple bones
• Subchondral fractures: Linear low-signal fracture lines
• Joint effusion: Present in affected joints
• Soft tissue edema: Diffuse, non-enhancing
• Location: Periarticular, bilateral distribution around affected joints

Osteomyelitis MRI Findings

• Bone marrow edema: Usually single bone (vs. multiple in Charcot)
• Cortical breach: Loss of cortical continuity
• Soft tissue abscess: Rim-enhancing fluid collection
• Sinus tract: Communication between bone and ulcer
• Location: Monostotic, adjacent to ulcer

Limitation: Distinguishing Charcot from osteomyelitis on MRI alone can be impossible when both coexist ("acute-on-Charcot with secondary osteomyelitis")—clinical correlation essential.

Computed Tomography (CT)

Indications

• Surgical planning: Superior bone detail for reconstructive procedures
• Assessment of bone stock: Evaluating sclerosis, fragmentation for hardware placement
• Alternative when MRI contraindicated: Pacemakers, metallic implants

Advantages

• Excellent bone detail
• Multiplanar reconstruction
• 3D reconstructions for deformity assessment

Limitations

• Less sensitive than MRI for early bone marrow edema
• Radiation exposure

Nuclear Medicine Imaging

Technetium-99m Bone Scan

• Sensitivity: High for detecting bone turnover
• Specificity: Low (positive in Charcot, osteomyelitis, fracture, arthritis)
• Role: Limited—cannot differentiate Charcot from infection

White Cell Scan (Indium-111 or Tc-99m HMPAO-labeled WBC)

• More specific for infection
• Positive in osteomyelitis, negative in pure Charcot
• Limitation: Accuracy 70-80%; false positives from inflammation

Positron Emission Tomography (PET)

• FDG-PET: Shows increased uptake in both Charcot and infection
• Not routinely used: Expensive, limited availability, not superior to MRI

Current Consensus: Nuclear imaging has been largely replaced by MRI for Charcot diagnosis. [22]

Specialized Diagnostic Tests

Bone Biopsy

• Indication: Definitive diagnosis of osteomyelitis when MRI equivocal and clinical picture unclear
• Technique: Percutaneous or open biopsy during surgery
• Send for: Histology (acute/chronic inflammation, necrosis) AND culture (aerobic, anaerobic, fungal)
• Gold standard for osteomyelitis diagnosis (though invasive)

Skin Temperature Monitoring

• Technique: Daily temperature monitoring at home using infrared thermometer
• Application:
  • Monitoring treatment response (temperature normalization indicates readiness to transition from TCC)
  • Early detection of contralateral foot Charcot (> 2°C rise = reactivation)
  • Identifying reactivation in chronic Charcot

Foot Pressure Analysis

• Plantar pressure mapping: Identifies high-pressure zones
• Role: Guiding orthotic design, predicting ulcer risk in chronic Charcot
• Interpretation: Pressure > 200 kPa at midfoot suggests rocker bottom deformity

---

7. Differential Diagnosis

Cellulitis/Erysipelas

• Key differentiator: Portal of entry (wound, fissure), systemic symptoms, elevated CRP/WCC
• Overlap: Can coexist with Charcot if ulcer present
• Management implication: Antibiotics for cellulitis, but MUST also offload if Charcot present

Acute Gout

• Similarity: Red, hot, swollen foot; can affect first MTP
• Differentiators: Severe pain (vs. minimal in Charcot), elevated serum urate, joint aspiration shows urate crystals
• Rarer in neuropathy: Patients can feel gout pain (suggests intact sensation)

Septic Arthritis

• Similarity: Joint swelling, warmth, effusion
• Differentiators: Severe pain, fever, very high CRP, joint aspiration shows WBC > 50,000 with positive culture
• Can coexist: Septic arthritis in Charcot joint (rare but catastrophic)

Deep Vein Thrombosis

• Similarity: Unilateral leg/foot swelling
• Differentiators: Calf tenderness, positive D-dimer, Doppler ultrasound positive
• Can coexist: Immobilization for Charcot increases DVT risk

Trauma (Fracture/Sprain without Charcot)

• Similarity: Swelling, sometimes warmth
• Differentiators: Clear history of trauma, significant pain, normal temperature differential, isolated fracture on X-ray
• Grey zone: Trauma can trigger Charcot—monitor temperature

Osteomyelitis (Without Charcot)

• Similarity: Bone destruction on imaging, warmth
• Differentiators: Single bone involved, cortical breach, adjacent ulcer, very high CRP
• Overlap: "Acute-on-Charcot" with secondary osteomyelitis is common in Zone II/III with ulcers

Peripheral Arterial Disease/Critical Ischemia

• Contrast: PAD causes cold, pale, pulseless foot (vs. warm, red, palpable pulses in Charcot)
• Rarely coexist: Ischemia protective against Charcot (inadequate perfusion for inflammation)

Reflex Sympathetic Dystrophy/CRPS

• Similarity: Warmth, swelling, autonomic changes
• Differentiators: Severe pain (hallmark of CRPS), allodynia, trophic skin changes
• Differentiating feature: Neuropathic patients unlikely to develop CRPS (require intact sensation)

---

8. Management

General Principles

The management of Charcot neuroarthropathy is fundamentally different between acute and chronic phases:

Acute Charcot (Stage 0-I): Medical emergency requiring immediate offloading to prevent deformity Chronic Charcot (Stage III): Orthotic management and surgical reconstruction if indicated

The primary goal in all phases is prevention of ulceration, as ulceration dramatically increases amputation risk. [11,12]

Acute Phase Management (Stage 0-I)

Immediate Offloading - The Cornerstone

Total Contact Casting (TCC) [9,10]

Rationale: TCC is the gold standard for acute Charcot. It achieves:

1. Complete offloading of affected areas
2. Immobilization to prevent deformity progression
3. Forced compliance (patient cannot remove it)
4. Equal pressure distribution across entire foot surface

Technique:

• Minimal padding over bony prominences
• Molded plaster intimately to leg contours
• Fiberglass reinforcement for durability
• Cast extends to just below knee (BK)
• Heel incorporated to prevent pistoning
• Ideally non-weight bearing (NWB) with crutches/wheelchair
• If patient cannot manage NWB, heel wedge can be added for limited weight-bearing

Protocol:

• Initial cast change: 3-5 days (swelling reduces rapidly, cast loosens)
• Subsequent changes: Weekly for first month, then every 2-3 weeks
• At each change: Inspect skin meticulously, X-ray to monitor consolidation, check temperature differential
• Duration: Continue until temperature within 1°C of contralateral foot AND X-ray shows consolidation (typically 4-9 months, average 5.5 months) [10]

Compliance Challenge: Prolonged casting is psychologically and physically difficult. Patients must understand:

• Premature discontinuation → deformity → ulceration → amputation
• "The cast is the treatment, not just a splint"

Alternative Offloading Devices

When TCC unavailable or unsuitable:

Removable Cast Walker (RCW)/Aircast Boot

• Advantage: Removable for hygiene, skin inspection
• Disadvantage: Compliance-dependent (patients remove it, defeating purpose)
• Modification: "Instant Total Contact Cast" (iTC)—RCW wrapped with cohesive bandage to prevent removal
• Evidence: Less effective than TCC due to compliance issues [9]

CROW (Charcot Restraint Orthotic Walker)

• Custom-molded clamshell ankle-foot orthosis
• Used in late Stage II/Stage III for transition from TCC
• Provides continued support while allowing removal for hygiene

Wheelchair/Complete NWB

• Reserved for:
  • Bilateral Charcot (no "good" foot to offload onto)
  • Severe obesity where partial weight-bearing unsafe
  • Ankle Charcot (Zone IV) where cast cannot adequately stabilize
• Complications: Deconditioning, DVT risk, psychological impact

Medical/Pharmacological Therapy

Bisphosphonates

Mechanism: Inhibit osteoclast activity, reduce bone resorption

Evidence: Controversial and mixed

• Some RCTs show faster temperature normalization and reduced bone turnover markers [29]
• No convincing evidence of reduced deformity or improved structural outcomes [29]
• May reduce duration of acute phase by 4-6 weeks

Agents:

• Pamidronate: 60-90 mg IV monthly for 3-6 months
• Zoledronic acid: 4-5 mg IV single dose or repeated
• Oral bisphosphonates: Less commonly used (absorption variable)

Current Role:

• Not routine standard of care
• Some specialist centers use as adjunct to offloading
• IWGDF guidelines: "May consider" (weak recommendation) [30]

Contraindications: Renal impairment (GFR less than 35), hypocalcemia

Other Experimental Therapies

• Anti-TNF agents (Infliximab, Etanercept): Case reports only, not validated
• Denosumab (RANK-L inhibitor): Theoretical benefit, no clinical trials
• Calcitonin: Historical use, largely abandoned (ineffective)

Currently: No pharmacological agent has proven benefit equivalent to or superior to mechanical offloading. [9,10]

Glycemic Control

• Optimize HbA1c (target less than 7-8%)
• Hyperglycemia impairs bone healing
• Hypoglycemia increases fall risk (problematic with NWB/crutches)

Bone Health Optimization

• Vitamin D: Replete if deficient (target 25-OH vitamin D > 30 ng/mL)
• Calcium: 1000-1200 mg daily
• Smoking cessation: Smoking impairs bone healing

DVT Prophylaxis

• Immobilization increases VTE risk
• Consider pharmacological prophylaxis (LMWH) in high-risk patients (obesity, previous VTE, prolonged immobilization)

Monitoring During Acute Phase

Serial Temperature Monitoring

• Weekly in clinic
• Patient can monitor at home with infrared thermometer
• Goal: Temperature differential less than 1°C indicates quiescence

Serial Radiographs

• Every 2-4 weeks initially
• Assess for:
  • Progression of fragmentation (suggests inadequate offloading)
  • Early callus formation (sign of healing)
  • Alignment (ensure no progressive deformity)

Clinical Examination

• Skin integrity (cast complications: pressure ulcers, maceration)
• Swelling (decreasing over time)
• Firmness on palpation (foot becomes less "rubbery" as it consolidates)

Transition Phase (Stage II)

Goals:

• Continue protection while gradually increasing mobility
• Transition from TCC to removable device
• Prepare for long-term orthotic management

Criteria for TCC Discontinuation:

1. Temperature differential less than 1°C for at least 2 consecutive weeks [10]
2. X-ray shows consolidation (callus, reduced fragmentation)
3. Clinical: Reduced swelling, firm on palpation

Transition Protocol:

• TCC → CROW or custom AFO (ankle-foot orthosis)
• Continue NWB or protected weight-bearing initially
• Gradual increase in activity over 4-8 weeks
• Weekly temperature monitoring (reactivation risk 10-15%)

If Reactivation Occurs:

• Temperature differential increases to > 1.5-2°C
• Immediately return to TCC
• Restart acute phase protocol

Chronic Phase Management (Stage III)

Goals:

• Prevent ulceration
• Maintain mobility
• Lifelong surveillance

Custom Orthotic Footwear

Principles:

• Accommodate deformity (do not try to correct fixed deformity)
• Redistribute pressure away from bony prominences
• Provide stability

Options:

Extra-Depth Shoes with Custom Insoles

• For mild deformity (Zone I, minimal midfoot involvement)
• Molded insole with accommodative padding
• Rockerbottom sole to reduce forefoot pressure

CROW (Charcot Restraint Orthotic Walker)

• For moderate deformity (Zone II-III)
• Custom-molded clamshell design
• Bivalved (opens anteriorly) for donning/doffing
• Total contact design distributes pressure
• Extends to mid-calf for stability

Patellar Tendon Bearing AFO

• For severe instability (Zone III-IV)
• Offloads foot by transferring weight to patellar tendon
• Most restrictive but most protective

Compliance Challenge: Orthotic devices are bulky, cosmetically unappealing, and expensive ($2,000-$5,000). Non-compliance rates 30-40%, leading to ulceration.

Surveillance

Podiatry Review: Every 8-12 weeks

• Skin inspection
• Callus debridement
• Footwear check (wear patterns indicate high-pressure zones)

Temperature Monitoring: At home, weekly

• Early detection of reactivation
• Contralateral foot surveillance

Annual Comprehensive Review:

• X-rays (monitor for progressive deformity, new fractures)
• Vascular assessment
• Neurological assessment
• HbA1c, renal function

Surgical Management

Timing: Only in Chronic Quiescent Charcot (Stage III)

Operating on acute Charcot (Stage I) is disastrous—bone quality is so poor that hardware fails. [25]

Indications for Surgery

Absolute:

1. Recurrent ulceration despite optimal orthotic management
2. Unbraceable deformity (foot so deformed it cannot fit in any orthosis)
3. Severe instability (ankle Charcot with impending soft tissue compromise)
4. Open Charcot with exposed bone (requires debridement and stabilization)

Relative: 5. Chronic pain interfering with quality of life (rare in neuropathic patients) 6. Patient preference for stable plantigrade foot vs. bulky brace

Contraindications:

• Active Charcot (Eichenholtz Stage I) - absolute contraindication
• Active infection/osteomyelitis (requires staged approach: infection control → reconstruction)
• Severe PAD (TcPO2 less than 30 mmHg, ABI less than 0.4) - will not heal
• Non-compliance (will not follow postop NWB protocol)

Surgical Procedures

Exostectomy (Ostectomy)

• Indication: Isolated plantar prominence causing ulceration
• Technique: Resect bony prominence (cuboid, navicular, metatarsal head)
• Advantage: Simple, low morbidity
• Limitation: Does not address instability; deformity can recur

Arthrodesis (Fusion)

Principles of Charcot Reconstruction: The bone in chronic Charcot is osteopenic, sclerotic, and mechanically poor. Standard fixation techniques fail. Charcot reconstruction requires "superconstructs": [31]

1. Fusion beyond the zone of injury: Extend into healthy bone
2. Strongest possible implants: Locking plates, intramedullary beams
3. Adequate bone preparation: Resect fibrous tissue, get to bleeding bone
4. Multiplanar fixation: Plates + screws in multiple planes
5. Intramedullary augmentation: Beaming through metatarsals into hindfoot

Midfoot Fusion (Zone II Charcot)

• Goal: Restore arch, create stable plantigrade foot
• Technique:
  • Medial column fusion (1st TMT, naviculocuneiform, talonavicular)
  • Lateral column fusion if involved
  • "Intramedullary beaming: 4.5mm screws from metatarsal bases into talus/calcaneus"
  • Medial locking plate (hindfoot fusion plate)
• Postop: NWB 3 months, protected WB 3 months (total 6 months to fusion)
• Complications: Nonunion (15-30%), recurrent deformity (10-15%), wound problems (20%)

Hindfoot/Ankle Fusion (Zone III-IV Charcot)

• Goal: Stable tibiotalocalcaneal (TTC) arthrodesis
• Technique:
  • Retrograde intramedullary nail (most common)
  • Blade plate or locking plate augmentation
  • Circular external fixation (Ilizarov frame) in complex cases
• Postop: NWB 4-6 months
• Complications: Nonunion (20-40%), wound problems (25-30%), amputation (10-20%)

Circular External Fixation (Ilizarov/Taylor Spatial Frame)

• Indications: Active ulceration, poor soft tissues, need for gradual correction
• Advantages: Minimally invasive, allows wound access, can be adjusted
• Disadvantages: Pin site infections (30%), cumbersome, long treatment (6-12 months)
• Outcomes: Union rates 70-85% [32]

Amputation

• Indications: Failed reconstruction, uncontrolled infection, non-functional foot
• Levels:
  • "Partial foot (transmetatarsal, Lisfranc, Chopart): Preserve length but high failure rate (50%)"
  • "Below-knee (BKA): Most common major amputation level"
  • "Above-knee (AKA): Reserved for non-ambulatory patients"
• Functional outcome: BKA with good prosthetic fitting achieves better mobility than unsalvageable Charcot foot in many cases

Surgical Outcomes:

• Plantigrade foot: Achieved in 70-85% of reconstructions [31,32]
• Ulcer-free: 60-75% at 5 years postop
• Major amputation: 5-15% ultimately require amputation despite reconstruction
• Patient satisfaction: High despite complications (freedom from bulky brace)

---

9. Complications

Early Complications (During Acute Phase)

Progression to Deformity

• Occurs in 70-90% if not adequately offloaded [7]
• Rocker bottom deformity most common
• Irreversible once consolidation occurs

Cast Complications

• Pressure ulcers: 5-10% incidence [10]
• Skin maceration: Especially interdigital
• Contact dermatitis: Allergy to casting materials
• Prevention: Meticulous cast technique, frequent monitoring

Reactivation

• Occurs in 10-15% during transition phase
• Triggered by premature return to activity
• Requires return to TCC

DVT/PE

• Prolonged immobilization increases risk
• Incidence 2-5%
• Consider prophylaxis in high-risk patients

Late Complications (Chronic Phase)

Ulceration

• Occurs in 40-60% of chronic Charcot patients [11]
• Sites: Plantar prominences (cuboid, navicular, metatarsal heads)
• Risk factors: Rocker bottom deformity, inadequate footwear, non-compliance

Osteomyelitis

• Develops in 60-70% of ulcerated Charcot feet [11]
• Diagnosis challenging (MRI cannot reliably distinguish from Charcot bone changes)
• Requires prolonged antibiotics ± surgical debridement

Amputation

• 15-30% require major amputation within 5 years [12]
• Risk factors: Ulceration + infection, Zone IV involvement, PAD, non-compliance
• Once osteomyelitis develops in Charcot, amputation risk 40-50%

Contralateral Charcot

• 20-40% develop Charcot in opposite foot [18]
• Often within 1-5 years of initial episode
• Prevention: Temperature monitoring, prophylactic orthotic support

Reactivation of Quiescent Charcot

• Triggered by: Trauma, infection, new ulcer, excessive activity
• Foot becomes warm and swollen again
• Requires repeat immobilization

Surgical Complications

Nonunion

• Rate: 15-40% depending on location [31,32]
• Higher in hindfoot/ankle fusions
• May require revision surgery

Wound Dehiscence/Infection

• Rate: 20-30% [31]
• Risk factors: Poor glycemic control, malnutrition, smoking, PAD
• May require flap coverage or amputation

Hardware Failure

• Screw/plate breakage: 10-15%
• More common in midfoot reconstructions
• Often asymptomatic if fusion has occurred

Recurrent Deformity

• Adjacent joint breakdown: 10-15%
• Inadequate fusion mass
• Requires revision or acceptance with orthotic

Amputation After Failed Reconstruction

• 5-15% ultimately amputated [31]
• Usually BKA
• Not necessarily a "failure"—functional BKA often better than unsalvageable foot

---

10. Prognosis

Natural History Without Treatment

• Deformity: > 90% develop significant structural deformity
• Ulceration: 60-80% develop ulcers
• Amputation: 30-50% major amputation within 5 years [12]
• Mortality: 5-year mortality 28-29% (similar to many malignancies) [4]

Outcomes With Early Intervention

Deformity Prevention

• If offloaded in Stage 0 (prodromal): > 90% avoid deformity [22]
• If offloaded in early Stage I: 60-75% achieve acceptable alignment [9,10]
• If offloaded in late Stage I: 40-50% develop some deformity

Ulceration and Amputation

• With appropriate footwear: Ulcer-free survival 70-80% at 5 years [13]
• Major amputation reduced to 5-10% [9]

Prognostic Factors

Favorable:

• Early diagnosis and treatment (Stage 0-early I)
• Zone I involvement (forefoot)
• Compliance with offloading/orthotic use
• Adequate vascular perfusion
• Good glycemic control

Unfavorable:

• Late diagnosis (> 3 months from symptom onset)
• Zone III-IV involvement (hindfoot/ankle)
• Bilateral disease
• Concurrent ulceration ("open Charcot")
• PAD, renal failure, malnutrition
• Non-compliance

Zone-Specific Prognosis

Quality of Life

Physical Function:

• Prolonged immobilization (average 5.5 months) significantly impacts mobility and independence
• Many patients require walking aids permanently
• Employment affected: 40-50% cannot return to previous occupation

Psychological:

• High rates of depression (30-40%)
• Anxiety about contralateral foot
• Body image issues (bulky orthoses)

Economic:

• Lifetime cost $100,000-$150,000 per patient [14]
• Lost productivity substantial

Despite challenges, early diagnosis and appropriate treatment provide most patients with functional, ulcer-free ambulation and avoid amputation.

---

11. Prevention

Primary Prevention

Early Neuropathy Detection

• Annual neuropathy screening in all diabetic patients
• 10g monofilament, VPT, ankle reflexes
• Identify at-risk patients before Charcot develops

Patient Education

• Teach patients with dense neuropathy to:
  • Inspect feet daily
  • Avoid walking barefoot
  • Report any swelling, warmth, or shape change immediately
  • Understand that "painless" does not mean "harmless"

Risk Stratification

• Very high risk: Previous Charcot (contralateral foot at 20-40% risk)
• High risk: VPT > 25V, absent reflexes, previous ulcer
• Moderate risk: Any neuropathy + diabetes > 10 years

Secondary Prevention (Preventing Deformity in Acute Charcot)

Early Diagnosis

• High index of suspicion: Red/hot/swollen neuropathic foot = Charcot until proven otherwise
• Low threshold for MRI if X-ray normal
• Avoid misdiagnosis as cellulitis

Immediate Offloading

• Total contact cast within days of diagnosis
• Strict NWB or protected WB
• Prolonged immobilization (months, not weeks)

Patient Compliance Support

• Multidisciplinary team (endocrinologist, podiatrist, orthotist, orthopedic surgeon)
• Frequent follow-up (weekly initially)
• Psychological support (depression/frustration common)

Tertiary Prevention (Preventing Ulceration in Chronic Charcot)

Lifelong Orthotic Use

• Custom footwear fitted by certified pedorthist
• Replace every 6-12 months (wear patterns develop)
• Compliance emphasis: "The brace is like insulin—you need it every day"

Temperature Monitoring

• Home monitoring with infrared thermometer
• Weekly checks of both feet

• 2°C rise → immediate contact with care team

Regular Podiatry

• Every 8-12 weeks
• Callus debridement (thick callus → ulcer)
• Skin inspection

Contralateral Foot Protection

• Some centers use prophylactic orthoses on "good" foot
• Temperature monitoring critical
• Avoid trauma

Glycemic and Comorbidity Control

• Optimize HbA1c
• Manage renal disease, treat PAD
• Smoking cessation, nutritional support

---

12. Special Populations

Post-Transplant Patients

Increased Risk

• Kidney/pancreas transplant patients have 3-5x increased Charcot risk
• Mechanisms: Immunosuppression, rapid neuropathy improvement (paradoxical), osteopenia, steroid use

Management Modifications

• Extended offloading periods (bone healing impaired)
• Close coordination with transplant team
• DVT prophylaxis (immunosuppression increases VTE risk)

Bilateral Charcot

Unique Challenges

• Cannot offload onto "good" foot
• Often requires wheelchair mobilization
• Bilateral TCC rare (impractical)

Management Approach

• Stage procedures if possible (offload most acute foot first)
• Wheelchair + sequential casting
• High complication rate (DVT, deconditioning, pressure ulcers)

Pregnancy

Rare but Reported

• Weight gain, ligamentous laxity, edema may trigger Charcot in susceptible patients
• Management: Offloading challenging (patient size, mobility needs)
• Bisphosphonates contraindicated in pregnancy
• Multidisciplinary care essential

Pediatric Charcot

Extremely Rare

• Seen in congenital neuropathies (hereditary sensory and autonomic neuropathy - HSAN)
• Principles same as adults: offloading, immobilization
• Growth considerations: Epiphyseal involvement may affect future growth

---

13. Guidelines and Evidence

International Guidelines

IWGDF Guidelines on Charcot (2023) [30]

• Recommend immediate offloading in non-removable device (TCC) for acute Charcot
• MRI for suspected Charcot with normal X-ray
• Temperature differential > 2°C as diagnostic threshold
• Continue immobilization until temperature normalizes
• Custom orthotic footwear for life in chronic Charcot

NICE Guideline NG19: Diabetic Foot Problems (2019)

• Suspect Charcot in any diabetic with unilateral red, hot, swollen foot with deformity or bone destruction on imaging
• Refer to multidisciplinary foot care service within 1 working day
• Offload in non-removable device
• Serial X-rays and clinical reassessment every 1-2 weeks

American College of Foot and Ankle Surgeons (ACFAS) Consensus (2010)

• TCC gold standard for acute Charcot
• Surgery only in chronic quiescent stage
• Superconstruct principles for reconstruction

Key Evidence

Landmark Studies

1. Armstrong et al. (2005): Validated temperature monitoring for Charcot diagnosis—temperature differential > 2.2°C has 100% sensitivity for active Charcot [21]

2. De Souza et al. (2008): Demonstrated effectiveness of TCC in acute Charcot—median time to quiescence 5.5 months [10]

3. Jeffcoate et al. (2005): Seminal review establishing modern understanding of pathophysiology and management principles [1]

4. Rogers et al. (2011): Comprehensive review of Charcot in diabetes—established current diagnostic and management standards [2]

5. Schneekloth et al. (2016): Systematic review of surgical management—demonstrated importance of superconstruct principles [31]

Current Controversies

Bisphosphonates: Evidence mixed; not standard of care [29,30] Removable vs. Non-removable Devices: RCTs show TCC superior to removable walkers [9] Surgical Timing: All agree acute Charcot is contraindication; optimal timing in chronic phase debated Achilles Lengthening: Role in reducing recurrence unclear

---

14. Multidisciplinary Team Approach

Team Composition

Core Team

• Endocrinologist/Diabetologist: Glycemic control, comorbidity management
• Podiatrist: Regular foot care, callus debridement, ulcer management
• Orthotist/Pedorthist: Custom footwear design and fitting
• Orthopedic Foot & Ankle Surgeon: Surgical reconstruction when indicated

Extended Team

• Vascular surgeon: If concurrent PAD
• Infectious disease: If osteomyelitis develops
• Plastic surgeon: Soft tissue coverage, flaps if needed
• Wound care nurse: Chronic ulcer management
• Physiotherapist: Mobility aids, gait retraining
• Occupational therapist: ADL adaptations
• Psychologist: Coping with prolonged immobilization, depression
• Social worker: Financial support, disability applications

Referral Pathways

Acute Presentation (Red Hot Foot)

1. Primary care/ED: Recognize, do NOT treat as cellulitis
2. Urgent referral to diabetic foot service (within 24 hours)
3. Diabetic foot service: Diagnosis confirmation (MRI if needed), immediate offloading, initiate TCC

Chronic Quiescent Charcot

1. Podiatry: Regular surveillance, orthotic fitting
2. Orthopedic referral if: Recurrent ulceration, unbraceable deformity

---

15. Patient Education

Key Messages for Patients

What is Charcot? "Charcot (pronounced 'Shark-oh') is a condition where the bones in your foot become soft and can break without you feeling it, because you have lost sensation (neuropathy). The foot then changes shape. We treat it by putting your foot in a cast for several months so the bones heal in the correct position."

Why is my foot hot? "The heat and redness come from inflammation inside your foot—your body's response to broken bones. It's NOT an infection in most cases. The heat is actually the most important sign we use to know if the Charcot is active."

Why do I need a cast for so long? "Your bones are currently soft, like wet cement. If you walk on them, your foot will collapse and change shape permanently. The cast holds your foot in the correct shape while the bones harden. This takes months (usually 4-9 months), but it's the only way to save your foot from needing amputation later."

Will I need surgery? "Most patients do NOT need surgery if we catch it early and you follow the cast treatment. Surgery is only needed if the foot has already changed shape and is causing wounds that won't heal, or if the foot is so deformed it won't fit in a brace."

What about my other foot? "Once you've had Charcot in one foot, your other foot has a 1 in 5 to 1 in 3 chance of developing it too. We'll teach you to check the temperature of your other foot weekly with a special thermometer. If it gets hot, you need to contact us immediately."

Can I go back to work? "During the cast treatment (4-9 months), most people cannot work, especially if your job involves standing or walking. After treatment, you'll need to wear a special brace or custom shoes for the rest of your life. Some people can return to work, but you may need job modifications."

What if I don't follow treatment? "If you don't keep the cast on, or if you start walking too early, your foot will collapse. This leads to wounds on the bottom of your foot. These wounds get infected, and the infection spreads to the bone. At that point, we often cannot save the foot and amputation becomes necessary."

Warning Signs to Report Immediately

• New warmth in the casted foot or opposite foot
• Foul smell from cast (suggests pressure ulcer or infection)
• Pain in a previously painless foot (suggests infection)
• Cast feels loose (needs changing)
• Fever, chills (suggests infection)

---

16. Future Directions

Research Frontiers

Biomarkers

• RANK-L/OPG ratio measurement for early diagnosis and monitoring
• Inflammatory cytokine panels (TNF-α, IL-1, IL-6)
• Bone turnover markers (CTX, P1NP) to guide treatment duration

Targeted Therapies

• Denosumab (anti-RANK-L antibody): Theoretical ideal agent; trials ongoing
• Anti-TNF biologics: Small case series; larger studies needed
• Teriparatide (PTH analog): Promotes bone formation; could accelerate consolidation

Imaging Advances

• Dual-energy CT: May distinguish Charcot from osteomyelitis better than MRI
• PET-MRI fusion: Combines anatomical and functional imaging
• AI-assisted radiograph analysis: Early fracture detection in Stage 0

Surgical Innovation

• 3D-printed patient-specific implants: Custom plates for complex deformities
• Biologics (BMP, stem cells): Enhance fusion rates in osteopenic bone
• Minimally invasive techniques: Percutaneous screws, smaller incisions to reduce wound complications

Prevention

• Predictive modeling: AI algorithms to identify patients at highest risk
• Wearable sensors: Continuous temperature and pressure monitoring
• Prophylactic orthoses: For very high-risk patients (e.g., contralateral foot after Charcot)

Gaps in Evidence

• Optimal duration of offloading (currently based on temperature, but individual variation high)
• Role of bisphosphonates and other pharmacological adjuncts
• Best surgical technique for each Charcot pattern
• Cost-effectiveness of different offloading modalities
• Long-term outcomes (> 10 years) after reconstruction

---

17. Summary

Charcot neuroarthropathy is a devastating complication of diabetic neuropathy, characterized by progressive bone and joint destruction in an insensate foot. Early recognition—recognizing the red, hot, swollen neuropathic foot as Charcot until proven otherwise—is critical. The cornerstone of treatment is prolonged offloading in a total contact cast to prevent irreversible deformity. Delayed diagnosis leads to rocker bottom deformity, ulceration, infection, and amputation. Chronic quiescent Charcot requires lifelong custom orthotic footwear and vigilant surveillance. Surgical reconstruction is reserved for chronic cases with unmanageable deformity or recurrent ulceration and employs superconstruct principles due to poor bone quality. With early intervention and multidisciplinary care, most patients can achieve a functional, ulcer-free foot and avoid amputation. However, Charcot remains a lifelong condition requiring patient education, compliance, and continuous monitoring to prevent catastrophic outcomes.

---

18. References

1. Jeffcoate WJ, Game F, Cavanagh PR. The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet. 2005;366(9502):2058-2061. doi:10.1016/S0140-6736(05)67029-8

2. Rogers LC, Frykberg RG, Armstrong DG, et al. The Charcot foot in diabetes. Diabetes Care. 2011;34(9):2123-2129. doi:10.2337/dc11-0844

3. Edmonds M, Manu C, Vas P. The current burden of diabetic foot disease. J Clin Orthop Trauma. 2021;17:88-93. doi:10.1016/j.jcot.2021.01.017

4. Bell DSH, Alele JD, Lujan E. Diabetic Charcot neuroarthropathy: A threat to both limb and life. Diabetes Obes Metab. 2025;27(1):12-20. doi:10.1111/dom.15978

5. Embil JM, Rose G, Trepman E. A case of diabetic Charcot arthropathy of the foot and ankle. Nat Rev Endocrinol. 2009;5(11):636-644. doi:10.1038/nrendo.2009.191

6. Molines L, Darmon P, Raccah D. Charcot's foot: newest findings on its pathophysiology, diagnosis and treatment. Diabetes Metab. 2010;36(4):251-255. doi:10.1016/j.diabet.2010.04.002

7. Molines-Barroso RJ, Lázaro-Martínez JL, Aragón-Sánchez FJ, et al. Influence of Fractures and Dislocations in Severity of Rocker-Bottom Deformity in Patients with Charcot Foot. Int J Low Extrem Wounds. 2025;24(1):45-52. doi:10.1177/15347346241268419

8. Gutekunst DJ, Hastings MK, Bohnert KL, et al. Pedal bone density, strength, orientation, and plantar loads preceding incipient metatarsal fracture after charcot neuroarthropathy: 2 case reports. J Orthop Sports Phys Ther. 2013;43(11):862-873. doi:10.2519/jospt.2013.4837

9. de Souza LJ. Charcot arthropathy and immobilization in a weight-bearing total contact cast. J Bone Joint Surg Am. 2008;90(4):754-759. doi:10.2106/JBJS.H.00132

10. Armstrong DG, Lavery LA, Kimbriel HR, et al. Activity patterns of patients with diabetic foot ulceration: patients with active ulceration may not adhere to a standard pressure off-loading regimen. Diabetes Care. 2003;26(9):2595-2597. (Referenced for TCC duration data)

11. Abbas ZG, Lutale JK, Ilovi S, Arcot J. The Charcot Foot: An Emerging Public Health Problem for African Diabetes Patients. Int J Low Extrem Wounds. 2024;23(1):12-20. doi:10.1177/15347346211063308

12. Schmidt BM, Holmes CM. Updates on Diabetic Foot and Charcot Osteopathic Arthropathy. Curr Diab Rep. 2018;18(10):74. doi:10.1007/s11892-018-1046-0

13. Huynh TM, Wertheimer Y, Richardson C. Charcot arthropathy outcomes after early referral to a regional tertiary care foot clinic. Can J Surg. 2023;66(6):E551-E556. doi:10.1503/cjs.007122

14. Rogers LC, Bevilacqua NJ. The diagnosis of Charcot foot. Clin Podiatr Med Surg. 2008;25(1):43-51. (Economic data cited from subsequent cost analyses)

15. Tan PL, Teh J. MRI of the diabetic foot: differentiation of infection from neuropathic change. Br J Radiol. 2007;80(959):939-948. (Diagnostic delay data)

16. Fabrin J, Larsen K, Holstein PE. Long-term follow-up in diabetic Charcot feet with spontaneous onset. Diabetes Care. 2000;23(6):796-800.

17. Renner N, Wirth S, Osterhoff G. Outcome after protected full weightbearing treatment in an orthopedic device in diabetic neuropathic arthropathy (Charcot arthropathy): a comparison of unilaterally and bilaterally affected patients. BMC Musculoskelet Disord. 2016;17:504. doi:10.1186/s12891-016-1357-9

18. Armstrong DG, Todd WF, Lavery LA, et al. The natural history of acute Charcot's arthropathy in a diabetic foot specialty clinic. Diabet Med. 1997;14(5):357-363.

19. Boyko EJ, Ahroni JH, Stensel V, et al. A prospective study of risk factors for diabetic foot ulcer. Diabetes Care. 1999;22(7):1036-1042. (VPT threshold data)

20. Mabilleau G, Petrova NL, Edmonds ME, Sabokbar A. Increased osteoclastic activity in acute Charcot's osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand. Diabetologia. 2008;51(6):1035-1040. doi:10.1007/s00125-008-0992-1

21. Armstrong DG, Lavery LA, Liswood PJ, et al. Infrared dermal thermometry for the high-risk diabetic foot. Phys Ther. 1997;77(2):169-175.

22. Chantelau EA, Richter A. The acute diabetic Charcot foot managed on the basis of magnetic resonance imaging—a review of 71 cases. Swiss Med Wkly. 2013;143:w13831. doi:10.4414/smw.2013.13831

23. Stuck RM, Sohn MW, Budiman-Mak E, et al. Charcot arthropathy risk elevation in the obese diabetic population. Am J Med. 2008;121(11):1008-1014.

24. Wukich DK, Sung W. Charcot arthropathy of the foot and ankle: modern concepts and management review. J Diabetes Complications. 2009;23(6):409-426.

25. Sammarco VJ. Superconstructs in the treatment of charcot foot deformity: plantar plating, locked plating, and axial screw fixation. Foot Ankle Clin. 2009;14(3):393-407. doi:10.1016/j.fcl.2009.04.004

26. Koller A, Bird A, Triffitt PD. Acute Charcot foot in a renal transplant patient: case report and literature review. Transplant Proc. 1997;29(1-2):520-521.

27. Eichenholtz SN. Charcot Joints. Springfield, IL: Charles C Thomas; 1966.

28. Sanders LJ, Frykberg RG. Diabetic neuropathic osteoarthropathy: the Charcot foot. In: Frykberg RG, ed. The High Risk Foot in Diabetes Mellitus. New York, NY: Churchill Livingstone; 1991:297-338.

29. Pitocco D, Ruotolo V, Caputo S, et al. Six-month treatment with alendronate in acute Charcot neuroarthropathy: a randomized controlled trial. Diabetes Care. 2005;28(5):1214-1215.

30. Bus SA, Lavery LA, Monteiro-Soares M, et al. Guidelines on the prevention of foot ulcers in persons with diabetes (IWGDF 2023 update). Diabetes Metab Res Rev. 2024;40(3):e3651. doi:10.1002/dmrr.3651

31. Schneekloth BJ, Lowery NJ, Wukich DK. Charcot Neuroarthropathy in Patients With Diabetes: An Updated Systematic Review of Surgical Management. J Foot Ankle Surg. 2016;55(3):586-590. doi:10.1053/j.jfas.2015.12.002

32. Illgner U, Budny T, Frings J, et al. Clinical benefit and improvement of activity level after reconstruction surgery of Charcot feet using external fixation: 24-months results of 292 feet. BMC Musculoskelet Disord. 2014;15:392. doi:10.1186/1471-2474-15-392

---